NEW YORK (GenomeWeb) – Cure-One announced today that it has secured the participation of Guardant Health and Foundation Medicine in its N1 Registry.
The registry aims to accomplish several goals, including helping patients to gain access to quality genomic testing; to gather data that can elucidate the genetic basis of malignancy in order to help physicians make decisions for their patients; to collect genomic data to elucidate the complexity, intricacy, and application of NGS testing; to help patients enroll in clinical trials; and to collect information on patients who have, or will, receive NGS testing, among other things.
Foundation Medicine and Guardant have been named as “cornerstone” laboratories for the registry, and will provide NGS testing for solid tumors and liquid biopsies for enrolling patients in N1, Cure-One said. Further terms of the agreements were not disclosed.
“Guardant Health is the world leader in liquid biopsies, and its participation with our N1 Registry is a testament to its commitment to advance the field of precision medicine, and to increase the availability of noninvasive comprehensive sequencing to advanced cancer patients,” Cure-One Founder and CEO Dane Dickson said in a statement.
“Foundation Medicine has long provided the highest quality of testing, while